Boston Scientific Quarterly Income Statement
NYSE: BSXHealth CareMedical/Dental InstrumentsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Boston Scientific revenue and earnings
In the quarter ended Jun 30, 2026, Boston Scientific generated $5.44 billion in revenue, up 7.5% from the same quarter a year earlier. Net income was $905.0 million (+13.8% year over year), for a net margin of 16.6% versus a median of 14.9% in the prior 5 quarters. Gross margin was 70.7% (up from 67.7%) and operating margin 21.6%.
Diluted earnings per share came in at $0.61, up from $0.53.
Summary generated from market data by MetaCap's automated system. Methodology
Boston Scientific income statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 5.44B | 5.20B | 5.29B | 5.07B | 5.06B | 4.66B | 4.56B | 4.21B | 4.12B | 3.86B | 3.73B | 3.53B |
| Revenue growth (YoY) | +7.53% | +11.58% | +15.90% | +20.34% | +22.84% | +20.93% | +22.44% | +19.34% | +14.48% | +13.78% | +14.90% | +11.26% |
| Cost of Revenue | 1.59B | 1.59B | 1.61B | 1.52B | 1.64B | 1.45B | 1.47B | 1.31B | 1.27B | 1.21B | 1.15B | 1.10B |
| Gross Profit | 3.85B | 3.61B | 3.68B | 3.54B | 3.42B | 3.21B | 3.10B | 2.90B | 2.85B | 2.65B | 2.58B | 2.43B |
| Operating Expenses | 2.67B | 2.51B | 2.85B | 2.49B | 2.60B | 2.29B | 2.42B | 2.16B | 2.33B | 1.97B | 2.00B | 1.73B |
| Research & Development | 554.00M | 516.00M | 569.00M | 514.00M | 526.00M | 443.00M | 459.00M | 407.00M | 383.00M | 366.00M | 363.00M | 356.00M |
| Selling, General & Admin | 1.80B | 1.78B | 1.83B | 1.74B | 1.72B | 1.60B | 1.61B | 1.56B | 1.45B | 1.36B | 1.38B | 1.24B |
| Operating Income | 1.18B | 1.10B | 825.00M | 1.05B | 819.00M | 921.00M | 675.00M | 733.00M | 520.00M | 675.00M | 584.00M | 693.00M |
| Interest Expense | 96.00M | 90.00M | 90.00M | 87.00M | 90.00M | 82.00M | 80.00M | 79.00M | 77.00M | 69.00M | 65.00M | 66.00M |
| Other Income (Expense) | -118.00M | 61.00M | -125.00M | -110.00M | 122.00M | -116.00M | -90.00M | -65.00M | -100.00M | -67.00M | -79.00M | -83.00M |
| Pretax Income | 1.06B | 1.16B | 700.00M | 939.00M | 941.00M | 805.00M | 585.00M | 669.00M | 420.00M | 608.00M | 505.00M | 610.00M |
| Income Tax | 155.00M | -176.00M | 30.00M | 183.00M | 146.00M | 133.00M | 23.00M | 200.00M | 98.00M | 115.00M | 1.00M | 105.00M |
| Net Income | 905.00M | 1.34B | 670.00M | 755.00M | 795.00M | 672.00M | 562.00M | 468.00M | 322.00M | 493.00M | 504.00M | 504.00M |
| Net Income growth (YoY) | +13.84% | +99.26% | +19.22% | +61.32% | +146.89% | +36.31% | +11.51% | -7.14% | +19.26% | +57.01% | +260.00% | +168.09% |
| EPS (Basic) | 0.62 | 0.90 | 0.45 | 0.51 | 0.54 | 0.46 | 0.38 | 0.32 | 0.22 | 0.34 | 0.35 | 0.34 |
| EPS (Diluted) | 0.61 | 0.90 | 0.45 | 0.51 | 0.53 | 0.45 | 0.38 | 0.32 | 0.22 | 0.33 | 0.34 | 0.34 |
| Shares Outstanding (Basic) | 1.47B | 1.48B | — | 1.48B | 1.48B | 1.48B | — | 1.47B | 1.47B | 1.47B | — | 1.46B |
| Shares Outstanding (Diluted) | 1.47B | 1.50B | — | 1.50B | 1.49B | 1.49B | — | 1.49B | 1.48B | 1.48B | — | 1.48B |
| EBITDA | 1.53B | 1.45B | 1.19B | 1.39B | 1.16B | 1.25B | 1.02B | 1.04B | 831.00M | 979.00M | 897.00M | 993.00M |
| Gross Margin | 70.71% | 69.46% | 69.60% | 69.93% | 67.65% | 68.84% | 67.86% | 68.83% | 69.17% | 68.67% | 69.23% | 68.78% |
| Operating Margin | 21.65% | 21.16% | 15.61% | 20.69% | 16.18% | 19.75% | 14.80% | 17.42% | 12.62% | 17.51% | 15.68% | 19.65% |
| Net Margin | 16.63% | 25.74% | 12.67% | 14.91% | 15.71% | 14.41% | 12.32% | 11.12% | 7.82% | 12.79% | 13.53% | 14.29% |
This table shows 12 quarterly periods of Boston Scientific's income statement, from Q2 2026 back to Q3 2023, across 20 line items including revenue, cost of revenue, gross profit. Values in USD; B = billions, M = millions. Fiscal periods follow BSX's reporting calendar. What is a income statement?